Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014
30 Abril 2014 - 1:07PM
Galapagos NV (Euronext: GLPG) has the honor to invite the
Shareholders, Warrant Holders, Directors and Statutory Auditor of
the Company to the Extraordinary General Shareholders' Meeting that
will be held on Monday 19 May 2014 at 2:00 p.m. (CET) at the
registered office of the Company. This is the second convening
notice, as the legally required quorum to discuss and resolve on
the agenda items was not reached at the first Meeting of 29 April
2014.
In order to be admitted to the Extraordinary
Shareholders' Meeting, the holders of securities issued by the
Company must comply with article 536 of the Belgian Companies
Code and article 29 of the articles of association of the
Company, and fulfill the formalities and make the notifications
described in the convening notice.
The convening notice and other relevant documents can be found
at
http://www.glpg.com/index.php/companyoverview/shareholder-information/shareholder-meetings/
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is
specialized in novel modes-of-action, with a large pipeline
comprising five Phase 2 studies (two led by GSK), one Phase 1
study, six pre-clinical, and 20 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, antibiotics,
metabolic disease, and other indications. In the field of
inflammation, AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further
development and commercialization of GLPG0634 after Phase 2B.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for
the treatment of rheumatoid arthritis and potentially other
inflammatory diseases, currently in Phase 2B studies in RA and in
Phase 2 in Crohn's disease. Galapagos has another selective
JAK1 inhibitor in Phase 2 in ulcerative colitis and psoriasis,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is
currently in a Proof-of-Concept Phase 2 study. GLPG1205 is a
first-in-class molecule that targets inflammatory disorders and has
completed Phase 1. AbbVie and Galapagos signed an agreement
in CF whereby they work collaboratively to develop and
commercialize oral drugs that address two mutations in the CFTR
gene, the G551D and F508del mutation. Potentiator GLPG1837 is
at the pre-clinical candidate stage. Galapagos has 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. Further
information at: www.glpg.com
CONTACT
Elizabeth Goodwin, Head of Corporate
Communications & Investor Relations Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
HUG#1781438
Aristocrat (PK) (USOTC:ASCC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Aristocrat (PK) (USOTC:ASCC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024